Zhixiong Ye

Publications by Year

Research Areas

Regulation of Appetite and Obesity, Biochemical Analysis and Sensing Techniques, melanin and skin pigmentation, Receptor Mechanisms and Signaling, Neuropeptides and Animal Physiology

Most-Cited Works

• → Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist(2002)190 cited
• → Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid(2006)92 cited
• → Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist(2004)42 cited
• → Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist(2005)37 cited
• → Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist(2010)23 cited
• → Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes(2015)23 cited
• → Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues(2000)21 cited
• → Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity(2010)21 cited
• → Chapter 4. Melanocortin-4 receptor agonists and antagonists: Chemistry and potential therapeutic utilities(2003)20 cited
• → The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes(2012)18 cited